Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence
Avant Technologies (OTCQB: AVAI) and Ainnova Tech have formed a joint venture called Ai-nova Acquisition Corp (AAC) to advance early disease detection using AI. The partnership focuses on commercializing Ainnova's VisionAI platform and Versatile Retinal Cameras in North America and Europe. VisionAI can detect diabetic retinopathy and other diseases through retinal scans with high accuracy. Ainnova will contribute its technology portfolio while Avant will handle capital requirements. The technology addresses a critical healthcare gap, as over 500 million people live with diabetes globally, and 30% may develop diabetic retinopathy. The AI in healthcare market is projected to grow from $6.9 billion to $67.4 billion by 2027.
Avant Technologies (OTCQB: AVAI) e Ainnova Tech hanno formata una joint venture chiamata Ai-nova Acquisition Corp (AAC) per avanzare nella rilevazione precoce delle malattie utilizzando l'intelligenza artificiale. La partnership si concentra sulla commercializzazione della piattaforma VisionAI di Ainnova e delle fotocamere retinali versatili in Nord America e in Europa. VisionAI è in grado di rilevare la retinopatia diabetica e altre malattie attraverso scansioni retiniche con elevata accuratezza. Ainnova contribuirà con il suo portfolio tecnologico, mentre Avant si occuperà delle esigenze di capitale. Questa tecnologia affronta una lacuna critica nel settore sanitario, poiché oltre 500 milioni di persone vivono con il diabete a livello globale, e il 30% potrebbe sviluppare retinopatia diabetica. Si prevede che il mercato dell'AI in sanità crescerà da 6,9 miliardi a 67,4 miliardi di dollari entro il 2027.
Avant Technologies (OTCQB: AVAI) y Ainnova Tech han formado una empresa conjunta llamada Ai-nova Acquisition Corp (AAC) para avanzar en la detección temprana de enfermedades utilizando inteligencia artificial. La asociación se centra en la comercialización de la plataforma VisionAI de Ainnova y las Cámaras Retinales Versátiles en América del Norte y Europa. VisionAI puede detectar la retinopatía diabética y otras enfermedades a través de escaneos de retina con alta precisión. Ainnova contribuirá con su cartera de tecnología, mientras que Avant se encargará de los requisitos de capital. Esta tecnología aborda una brecha crítica en la atención médica, ya que más de 500 millones de personas viven con diabetes en todo el mundo, y el 30% podría desarrollar retinopatía diabética. Se prevé que el mercado de la IA en atención médica crezca de 6,9 mil millones a 67,4 mil millones de dólares para 2027.
Avant Technologies (OTCQB: AVAI)와 Ainnova Tech는 AI를 사용하여 조기 질병 탐지를 발전시키기 위한 합작 투자인 Ai-nova Acquisition Corp (AAC)을 설립했습니다. 이 파트너십은 Ainnova의 VisionAI 플랫폼과 다목적 망막 카메라를 북미와 유럽에서 상용화하는 데 초점을 맞추고 있습니다. VisionAI는 높은 정확도로 망막 스캔을 통해 당뇨병성 망막병증 및 기타 질병을 감지할 수 있습니다. Ainnova는 기술 포트폴리오를 제공하고 Avant는 자본 요건을 처리할 것입니다. 이 기술은 전 세계적으로 5억 명 이상이 당뇨병으로 생활하고 있으며, 30%가 당뇨병성 망막병증으로 발전할 수 있는 중대한 의료 공백을 해소합니다. 헬스케어 AI 시장은 2027년까지 69억 달러에서 674억 달러로 성장할 것으로 예상됩니다.
Avant Technologies (OTCQB: AVAI) et Ainnova Tech ont formé une coentreprise appelée Ai-nova Acquisition Corp (AAC) pour faire avancer la détection précoce des maladies grâce à l'IA. Le partenariat se concentre sur la commercialisation de la plateforme VisionAI d'Ainnova et des caméras rétiniennes polyvalentes en Amérique du Nord et en Europe. VisionAI peut détecter la rétinopathie diabétique et d'autres maladies via des scans rétiniens avec une haute précision. Ainnova contribuera avec son portefeuille technologique tandis qu'Avant s'occupera des besoins en capital. La technologie répond à une lacune critique dans le domaine de la santé, car plus de 500 millions de personnes vivent avec le diabète dans le monde, et 30 % pourraient développer une rétinopathie diabétique. Le marché de l'IA en santé devrait passer de 6,9 milliards à 67,4 milliards de dollars d'ici 2027.
Avant Technologies (OTCQB: AVAI) und Ainnova Tech haben ein Joint Venture namens Ai-nova Acquisition Corp (AAC) gegründet, um die frühzeitige Erkennung von Krankheiten mithilfe von KI voranzutreiben. Die Partnerschaft konzentriert sich auf die Kommerzialisierung der VisionAI Plattform von Ainnova und der vielseitigen retinalen Kameras in Nordamerika und Europa. VisionAI kann diabetische Retinopathie und andere Krankheiten durch hochpräzise Netzhautuntersuchungen erkennen. Ainnova wird seinTechnologieportfolio beisteuern, während Avant sich um die Kapitalanforderungen kümmern wird. Diese Technologie schließt eine kritische Lücke im Gesundheitswesen, da über 500 Millionen Menschen weltweit mit Diabetes leben, von denen 30 % möglicherweise eine diabetische Retinopathie entwickeln werden. Der Markt für KI im Gesundheitswesen wird bis 2027 voraussichtlich von 6,9 Milliarden auf 67,4 Milliarden Dollar wachsen.
- Strategic joint venture to commercialize AI healthcare technology in North America and Europe
- Access to existing commercial agreements with pharma companies, clinics, and insurance companies
- Targeting large market opportunity with 500 million diabetic patients globally
- Operating in rapidly growing AI healthcare market projected to reach $67.4B by 2027
- Technology addresses critical healthcare gap with 49% diagnostic error rate in diabetic retinopathy
- Capital requirements burden falls on Avant Technologies
- Operating in highly competitive AI healthcare market
- Success dependent on market adoption and regulatory approvals
LAS VEGAS, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), and Ainnova Tech, Inc., (Ainnova) a leading healthcare technology (healthtech) company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced the companies have entered into a joint venture and licensing agreement with the formation of Ai-nova Acquisition Corp (AAC). The partnership was formed to advance and commercialize Ainnova’s technology portfolio, including its “VisionAI” platform and its “Versatile Retinal Cameras.”
Ainnova will contribute to AAC its proprietary technology portfolio, including VisionAI and its retinal camera technology, and the licensing rights for AAC to develop, maintain, and commercialize the technology portfolio in both North America (United States and Canada) and Europe, while Avant will be responsible for the capital requirements to operate AAC.
VisionAI is a cutting-edge, AI-driven platform that can detect diabetic retinopathy and other retinal diseases, as well as diseases unrelated to the retina like cardiovascular disease and potentially even Alzheimer’s with high accuracy and speed using retinal scans. Meanwhile, Ainnova’s next-generation versatile retinal cameras are seamlessly integrated with VisionAI for precise retinal scans. Along with the VisionAI software, Ainnova’s retinal cameras, offer AAC SaaS + retinal camera commercialization opportunities with opticians and eye care centers in two extremely profitable markets, North America and Europe.
Ainnova and Avant’s partnership seeks to make retinal scanning a new standard in primary care and basic health services by diagnosing a host of diseases early through a simple visual test that AAC can offer as a scalable and accessible solution.
Vinicio Vargas, Chief Executive Officer of Ainnova, commenting on the partnership said, “This joint venture aligns perfectly with our long-term goals, and as we work together to push the boundaries of what’s possible in the healthtech sector, we look forward to setting new standards and bringing transformative solutions to patients around the world in an accessible way.”
With over 500 million people living with diabetes globally, VisionAI is designed to detect the early markers of diseases like diabetic retinopathy, which is the leading cause of blindness among working age adults. Over
Unfortunately, there aren’t enough ophthalmologists globally. And
According to Ainnova, the diagnostic error rate in diabetic retinopathy is about
This partnership makes sense for Avant and its shareholders given the AI in healthcare market is projected to grow from
About Ainnova Tech, Inc.
Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas, founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce VisionAI - our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.
About Avant Technologies, Inc.
Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.
More information about Avant can be found at https://avanttechnologies.com
You can also follow us on social media at:
https://twitter.com/AvantTechAI
https://www.linkedin.com/company/avant-technologies-ai
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI
Forward-Looking Statements
Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
Contact:
Avant Technologies, Inc.
info@avanttechnologies.com
FAQ
What is the purpose of Avant Technologies (AVAI) joint venture with Ainnova Tech?
What diseases can Avant Technologies' (AVAI) VisionAI platform detect?
What is the market potential for Avant Technologies' (AVAI) AI healthcare technology?
How will responsibilities be divided in Avant Technologies' (AVAI) joint venture?
